{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:38:30Z","timestamp":1790807910254,"version":"4.1.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,6,9]],"date-time":"2018-06-09T00:00:00Z","timestamp":1528502400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s00467-018-3989-0","type":"journal-article","created":{"date-parts":[[2018,6,9]],"date-time":"2018-06-09T08:27:58Z","timestamp":1528532878000},"page":"1311-1323","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy"],"prefix":"10.1007","volume":"34","author":[{"given":"Marina","family":"Noris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Donadelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,9]]},"reference":[{"key":"3989_CR1","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00467-009-1322-7","volume":"25","author":"B Alchi","year":"2010","unstructured":"Alchi B, Jayne D (2010) Membranoproliferative glomerulonephritis. Pediatr Nephrol 25:1409\u20131418","journal-title":"Pediatr Nephrol"},{"key":"3989_CR2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1053\/j.ajkd.2015.03.040","volume":"66","author":"M Noris","year":"2015","unstructured":"Noris M, Remuzzi G (2015) Glomerular diseases dependent on complement activation, including atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis, and C3 glomerulopathy: Core Curriculum 2015. Am J Kidney Dis 66:359\u2013375","journal-title":"Am J Kidney Dis"},{"key":"3989_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/nrneph.2014.217","volume":"11","author":"HT Cook","year":"2015","unstructured":"Cook HT, Pickering MC (2015) Histopathology of MPGN and C3 glomerulopathies. Nat Rev Nephrol 11:14\u201322","journal-title":"Nat Rev Nephrol"},{"key":"3989_CR4","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/0090-1229(78)90160-5","volume":"10","author":"M Levy","year":"1978","unstructured":"Levy M, Gubler MC, Sich M, Beziau A, Habib R (1978) Immunopathology of membranoproliferative glomerulonephritis with subendothelial deposits (type I MPGN). Clin Immunol Immunopathol 10:477\u2013492","journal-title":"Clin Immunol Immunopathol"},{"key":"3989_CR5","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1681\/ASN.2005010078","volume":"16","author":"GB Appel","year":"2005","unstructured":"Appel GB, Cook HT, Hageman G, Jennette JC, Kashgarian M, Kirschfink M, Lambris JD, Lanning L, Lutz HU, Meri S, Rose NR, Salant DJ, Sethi S, Smith RJ, Smoyer W, Tully HF, Tully SP, Walker P, Welsh M, Wurzner R, Zipfel PF (2005) Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol 16:1392\u20131403","journal-title":"J Am Soc Nephrol"},{"key":"3989_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF00433081","volume":"376","author":"D Anders","year":"1977","unstructured":"Anders D, Agricola B, Sippel M, Thoenes W (1977) Basement membrane changes in membranoproliferative glomerulonephritis. II. Characterization of a third type by silver impregnation of ultra thin sections. Virchows Arch A Pathol Anat Histol 376:1\u201319","journal-title":"Virchows Arch A Pathol Anat Histol"},{"key":"3989_CR7","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.semnephrol.2011.06.005","volume":"31","author":"S Sethi","year":"2011","unstructured":"Sethi S, Fervenza FC (2011) Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. Semin Nephrol 31:341\u2013348","journal-title":"Semin Nephrol"},{"key":"3989_CR8","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMra1108178","volume":"366","author":"S Sethi","year":"2012","unstructured":"Sethi S, Fervenza FC (2012) Membranoproliferative glomerulonephritis\u2014a new look at an old entity. N Engl J Med 366:1119\u20131131","journal-title":"N Engl J Med"},{"key":"3989_CR9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.molimm.2016.01.010","volume":"71","author":"P Iatropoulos","year":"2016","unstructured":"Iatropoulos P, Noris M, Mele C, Piras R, Valoti E, Bresin E, Curreri M, Mondo E, Zito A, Gamba S, Bettoni S, Murer L, Fremeaux-Bacchi V, Vivarelli M, Emma F, Daina E, Remuzzi G (2016) Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Mol Immunol 71:131\u2013142","journal-title":"Mol Immunol"},{"key":"3989_CR10","doi-asserted-by":"publisher","first-page":"4288","DOI":"10.1093\/ndt\/gfs288","volume":"27","author":"FC Fervenza","year":"2012","unstructured":"Fervenza FC, Sethi S, Glassock RJ (2012) Idiopathic membranoproliferative glomerulonephritis: does it exist? Nephrol Dial Transplant 27:4288\u20134294","journal-title":"Nephrol Dial Transplant"},{"key":"3989_CR11","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/ki.2013.377","volume":"84","author":"MC Pickering","year":"2013","unstructured":"Pickering MC, D'Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, Alpers CE, Bajema IM, Bedrosian C, Braun M, Doyle M, Fakhouri F, Fervenza FC, Fogo AB, Fremeaux-Bacchi V, Gale DP, Goicoechea de Jorge E, Griffin G, Harris CL, Holers VM, Johnson S, Lavin PJ, Medjeral-Thomas N, Paul Morgan B, Nast CC, Noel LH, Peters DK, Rodriguez de Cordoba S, Servais A, Sethi S, Song WC, Tamburini P, Thurman JM, Zavros M, Cook HT (2013) C3 glomerulopathy: consensus report. Kidney Int 84:1079\u20131089","journal-title":"Kidney Int"},{"key":"3989_CR12","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/ki.2013.340","volume":"85","author":"J Hou","year":"2014","unstructured":"Hou J, Markowitz GS, Bomback AS, Appel GB, Herlitz LC, Barry Stokes M, D'Agati VD (2014) Toward a working definition of C3 glomerulopathy by immunofluorescence. Kidney Int 85:450\u2013456","journal-title":"Kidney Int"},{"key":"3989_CR13","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/ki.2012.63","volume":"82","author":"A Servais","year":"2012","unstructured":"Servais A, Noel LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, Macher MA, Zuber J, Karras A, Provot F, Moulin B, Grunfeld JP, Niaudet P, Lesavre P, Fremeaux-Bacchi V (2012) Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 82:454\u2013464","journal-title":"Kidney Int"},{"key":"3989_CR14","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.semnephrol.2013.08.001","volume":"33","author":"M Noris","year":"2013","unstructured":"Noris M, Remuzzi G (2013) Overview of complement activation and regulation. Semin Nephrol 33:479\u2013492","journal-title":"Semin Nephrol"},{"key":"3989_CR15","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/ni.1923","volume":"11","author":"D Ricklin","year":"2010","unstructured":"Ricklin D, Hajishengallis G, Yang K, Lambris JD (2010) Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11:785\u2013797","journal-title":"Nat Immunol"},{"key":"3989_CR16","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0065-2776(08)04004-2","volume":"104","author":"PJ Lachmann","year":"2009","unstructured":"Lachmann PJ (2009) The amplification loop of the complement pathways. Adv Immunol 104:115\u2013149","journal-title":"Adv Immunol"},{"key":"3989_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12915-015-0203-8","volume":"13","author":"ET Berends","year":"2015","unstructured":"Berends ET, Gorham RD Jr, Ruyken M, Soppe JA, Orhan H, Aerts PC, de Haas CJ, Gros P, Rooijakkers SH (2015) Molecular insights into the surface-specific arrangement of complement C5 convertase enzymes. BMC Biol 13:93","journal-title":"BMC Biol"},{"key":"3989_CR18","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa0810739","volume":"361","author":"M Delvaeye","year":"2009","unstructured":"Delvaeye M, Noris M, De Vriese A, Esmon CT, Esmon NL, Ferrell G, Del-Favero J, Plaisance S, Claes B, Lambrechts D, Zoja C, Remuzzi G, Conway EM (2009) Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 361:345\u2013357","journal-title":"N Engl J Med"},{"key":"3989_CR19","first-page":"2024","volume":"119","author":"ER Podack","year":"1977","unstructured":"Podack ER, Kolb WP, Muller-Eberhard HJ (1977) The SC5b-7 complex: formation, isolation, properties. and subunit composition J Immunol 119:2024\u20132029","journal-title":"and subunit composition J Immunol"},{"key":"3989_CR20","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.4049\/jimmunol.151.4.2159","volume":"151","author":"J Tschopp","year":"1993","unstructured":"Tschopp J, Chonn A, Hertig S, French LE (1993) Clusterin, the human apolipoprotein and complement inhibitor, binds to complement C7, C8 beta, and the b domain of C9. J Immunol 151:2159\u20132165","journal-title":"J Immunol"},{"key":"3989_CR21","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1681\/ASN.2017030258","volume":"29","author":"P Iatropoulos","year":"2018","unstructured":"Iatropoulos P, Daina E, Curreri M, Piras R, Valoti E, Mele C, Bresin E, Gamba S, Alberti M, Breno M, Perna A, Bettoni S, Sabadini E, Murer L, Vivarelli M, Noris M, Remuzzi G (2018) Cluster analysis identifies distinct pathogenetic patterns in C3 glomerulopathies\/immune complex-mediated membranoproliferative GN. J Am Soc Nephrol 29:283\u2013294","journal-title":"J Am Soc Nephrol"},{"key":"3989_CR22","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1126\/science.164.3878.436","volume":"164","author":"RE Spitzer","year":"1969","unstructured":"Spitzer RE, Vallota EH, Forristal J, Sudora E, Stitzel A, Davis NC, West CD (1969) Serum C'3 lytic system in patients with glomerulonephritis. Science 164:436\u2013437","journal-title":"Science"},{"key":"3989_CR23","doi-asserted-by":"crossref","first-page":"755","DOI":"10.4049\/jimmunol.123.2.755","volume":"123","author":"MR Daha","year":"1979","unstructured":"Daha MR, van Es LA (1979) Further evidence for the antibody nature of C3 nephritic factor (C3NeF). J Immunol 123:755\u2013758","journal-title":"J Immunol"},{"key":"3989_CR24","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.kint.2017.04.017","volume":"92","author":"MC Marinozzi","year":"2017","unstructured":"Marinozzi MC, Chauvet S, Le Quintrec M, Mignotet M, Petitprez F, Legendre C, Cailliez M, Deschenes G, Fischbach M, Karras A, Nobili F, Pietrement C, Dragon-Durey MA, Fakhouri F, Roumenina LT, Fremeaux-Bacchi V (2017) C5 nephritic factors drive the biological phenotype of C3 glomerulopathies. Kidney Int 92:1232\u20131241","journal-title":"Kidney Int"},{"key":"3989_CR25","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/ki.2012.250","volume":"82","author":"D Paixao-Cavalcante","year":"2012","unstructured":"Paixao-Cavalcante D, Lopez-Trascasa M, Skattum L, Giclas PC, Goodship TH, de Cordoba SR, Truedsson L, Morgan BP, Harris CL (2012) Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation. Kidney Int 82:1084\u20131092","journal-title":"Kidney Int"},{"key":"3989_CR26","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s10875-016-0290-5","volume":"36","author":"AM Blom","year":"2016","unstructured":"Blom AM, Corvillo F, Magda M, Stasilojc G, Nozal P, Perez-Valdivia MA, Cabello-Chaves V, Rodriguez de Cordoba S, Lopez-Trascasa M, Okroj M (2016) Testing the activity of complement convertases in serum\/plasma for diagnosis of C4NeF-mediated C3 glomerulonephritis. J Clin Immunol 36:517\u2013527","journal-title":"J Clin Immunol"},{"key":"3989_CR27","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1053\/j.ajkd.2017.07.004","volume":"70","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Meyer NC, Fervenza FC, Lau W, Keenan A, Cara-Fuentes G, Shao D, Akber A, Fremeaux-Bacchi V, Sethi S, Nester CM, Smith RJH (2017) C4 nephritic factors in C3 glomerulopathy: a case series. Am J Kidney Dis 70:834\u2013843","journal-title":"Am J Kidney Dis"},{"key":"3989_CR28","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2215\/CJN.07900811","volume":"7","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Meyer NC, Wang K, Nishimura C, Frees K, Jones M, Katz LM, Sethi S, Smith RJ (2012) Causes of alternative pathway dysregulation in dense deposit disease. Clin J Am Soc Nephrol 7:265\u2013274","journal-title":"Clin J Am Soc Nephrol"},{"key":"3989_CR29","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.molimm.2010.02.002","volume":"47","author":"S Strobel","year":"2010","unstructured":"Strobel S, Zimmering M, Papp K, Prechl J, Jozsi M (2010) Anti-factor B autoantibody in dense deposit disease. Mol Immunol 47:1476\u20131483","journal-title":"Mol Immunol"},{"key":"3989_CR30","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1681\/ASN.2016030343","volume":"28","author":"MC Marinozzi","year":"2017","unstructured":"Marinozzi MC, Roumenina LT, Chauvet S, Hertig A, Bertrand D, Olagne J, Frimat M, Ulinski T, Deschenes G, Burtey S, Delahousse M, Moulin B, Legendre C, Fremeaux-Bacchi V, Le Quintrec M (2017) Anti-factor B and anti-C3b autoantibodies in C3 glomerulopathy and Ig-associated membranoproliferative GN. J Am Soc Nephrol 28:1603\u20131613","journal-title":"J Am Soc Nephrol"},{"key":"3989_CR31","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1056\/NEJMc1107484","volume":"365","author":"Q Chen","year":"2011","unstructured":"Chen Q, Muller D, Rudolph B, Hartmann A, Kuwertz-Broking E, Wu K, Kirschfink M, Skerka C, Zipfel PF (2011) Combined C3b and factor B autoantibodies and MPGN type II. N Engl J Med 365:2340\u20132342","journal-title":"N Engl J Med"},{"key":"3989_CR32","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.molimm.2012.05.009","volume":"52","author":"TH Goodship","year":"2012","unstructured":"Goodship TH, Pappworth IY, Toth T, Denton M, Houlberg K, McCormick F, Warland D, Moore I, Hunze EM, Staniforth SJ, Hayes C, Cavalcante DP, Kavanagh D, Strain L, Herbert AP, Schmidt CQ, Barlow PN, Harris CL, Marchbank KJ (2012) Factor H autoantibodies in membranoproliferative glomerulonephritis. Mol Immunol 52:200\u2013206","journal-title":"Mol Immunol"},{"key":"3989_CR33","doi-asserted-by":"publisher","first-page":"5129","DOI":"10.4049\/jimmunol.1402770","volume":"194","author":"C Blanc","year":"2015","unstructured":"Blanc C, Togarsimalemath SK, Chauvet S, Le Quintrec M, Moulin B, Buchler M, Jokiranta TS, Roumenina LT, Fremeaux-Bacchi V, Dragon-Durey MA (2015) Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target two diseases. J Immunol 194:5129\u20135138","journal-title":"J Immunol"},{"key":"3989_CR34","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.molimm.2015.03.012","volume":"67","author":"PF Zipfel","year":"2015","unstructured":"Zipfel PF, Skerka C, Chen Q, Wiech T, Goodship T, Johnson S, Fremeaux-Bacchi V, Nester C, de Cordoba SR, Noris M, Pickering M, Smith R (2015) The role of complement in C3 glomerulopathy. Mol Immunol 67:21\u201330","journal-title":"Mol Immunol"},{"key":"3989_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4049\/jimmunol.116.1.1","volume":"116","author":"MR Daha","year":"1976","unstructured":"Daha MR, Fearon DT, Austen KF (1976) C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol 116:1\u20137","journal-title":"J Immunol"},{"key":"3989_CR36","doi-asserted-by":"publisher","first-page":"3980","DOI":"10.1073\/pnas.74.9.3980","volume":"74","author":"AE Davis 3rd","year":"1977","unstructured":"Davis AE 3rd, Ziegler JB, Gelfand EW, Rosen FS, Alper CA (1977) Heterogeneity of nephritic factor and its identification as an immunoglobulin. Proc Natl Acad Sci U S A 74:3980\u20133983","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3989_CR37","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1073\/pnas.73.9.3268","volume":"73","author":"JM Weiler","year":"1976","unstructured":"Weiler JM, Daha MR, Austen KF, Fearon DT (1976) Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci U S A 73:3268\u20133272","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3989_CR38","first-page":"449","volume":"68","author":"S Ito","year":"1989","unstructured":"Ito S, Tamura N, Fujita T (1989) Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor. Immunology 68:449\u2013452","journal-title":"Immunology"},{"key":"3989_CR39","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0022-1759(01)00295-2","volume":"251","author":"E Jelezarova","year":"2001","unstructured":"Jelezarova E, Schlumberger M, Sadallah S, Spath PJ, Schifferli JA, Lutz HU (2001) A C3 convertase assay for nephritic factor functional activity. J Immunol Methods 251:45\u201352","journal-title":"J Immunol Methods"},{"key":"3989_CR40","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/0022-1759(90)90234-M","volume":"131","author":"H Ohi","year":"1990","unstructured":"Ohi H, Watanabe S, Fujita T, Seki M, Hatano M (1990) Detection of C3bBb-stabilizing activity (C3 nephritic factor) in the serum from patients with membranoproliferative glomerulonephritis. J Immunol Methods 131:71\u201376","journal-title":"J Immunol Methods"},{"key":"3989_CR41","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1084\/jem.138.6.1305","volume":"138","author":"DT Fearon","year":"1973","unstructured":"Fearon DT, Austen KF, Ruddy S (1973) Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement. J Exp Med 138:1305\u20131313","journal-title":"J Exp Med"},{"key":"3989_CR42","first-page":"450","volume":"65","author":"YC Ng","year":"1986","unstructured":"Ng YC, Peters DK (1986) C3 nephritic factor (C3NeF): dissociation of cell-bound and fluid phase stabilization of alternative pathway C3 convertase. Clin Exp Immunol 65:450\u2013457","journal-title":"Clin Exp Immunol"},{"key":"3989_CR43","first-page":"811","volume":"9","author":"V Fremeaux-Bacchi","year":"1994","unstructured":"Fremeaux-Bacchi V, Weiss L, Brun P, Kazatchkine MD (1994) Selective disappearance of C3NeF IgG autoantibody in the plasma of a patient with membranoproliferative glomerulonephritis following renal transplantation. Nephrol Dial Transplant 9:811\u2013814","journal-title":"Nephrol Dial Transplant"},{"key":"3989_CR44","first-page":"12","volume":"32","author":"DM Scott","year":"1978","unstructured":"Scott DM, Amos N, Sissons JG, Lachmann PJ, Peters DK (1978) The immunogloblin nature of nephritic factor (NeF). Clin Exp Immunol 32:12\u201324","journal-title":"Clin Exp Immunol"},{"key":"3989_CR45","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/0090-1229(90)90144-F","volume":"56","author":"Y Tanuma","year":"1990","unstructured":"Tanuma Y, Ohi H, Hatano M (1990) Two types of C3 nephritic factor: properdin-dependent C3NeF and properdin-independent C3NeF. Clin Immunol Immunopathol 56:226\u2013238","journal-title":"Clin Immunol Immunopathol"},{"key":"3989_CR46","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.2215\/CJN.01820214","volume":"9","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Nester CM, Martin B, Skjoedt MO, Meyer NC, Shao D, Borsa N, Palarasah Y, Smith RJ (2014) Defining the complement biomarker profile of C3 glomerulopathy. Clin J Am Soc Nephrol 9:1876\u20131882","journal-title":"Clin J Am Soc Nephrol"},{"key":"3989_CR47","first-page":"73","volume":"65","author":"TE Mollnes","year":"1986","unstructured":"Mollnes TE, Ng YC, Peters DK, Lea T, Tschopp J, Harboe M (1986) Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro. Clin Exp Immunol 65:73\u201379","journal-title":"Clin Exp Immunol"},{"key":"3989_CR48","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/j.1365-2249.1992.tb06984.x","volume":"89","author":"H Ohi","year":"1992","unstructured":"Ohi H, Watanabe S, Fujita T, Yasugi T (1992) Significance of C3 nephritic factor (C3NeF) in non-hypocomplementaemic serum with membranoproliferative glomerulonephritis (MPGN). Clin Exp Immunol 89:479\u2013484","journal-title":"Clin Exp Immunol"},{"key":"3989_CR49","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1681\/ASN.2015020184","volume":"26","author":"AS Vriese De","year":"2015","unstructured":"De Vriese AS, Sethi S, Van Praet J, Nath KA, Fervenza FC (2015) Kidney disease caused by dysregulation of the complement alternative pathway: an etiologic approach. J Am Soc Nephrol 26:2917\u20132929","journal-title":"J Am Soc Nephrol"},{"key":"3989_CR50","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1034\/j.1399-3038.2001.012003166.x","volume":"12","author":"R Schwertz","year":"2001","unstructured":"Schwertz R, Rother U, Anders D, Gretz N, Scharer K, Kirschfink M (2001) Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: a long-term follow-up. Pediatr Allergy Immunol 12:166\u2013172","journal-title":"Pediatr Allergy Immunol"},{"key":"3989_CR51","first-page":"240","volume":"18","author":"FP Schena","year":"1982","unstructured":"Schena FP, Pertosa G, Stanziale P, Vox E, Pecoraro C, Andreucci VE (1982) Biological significance of the C3 nephritic factor in membranoproliferative glomerulonephritis. Clin Nephrol 18:240\u2013246","journal-title":"Clin Nephrol"},{"key":"3989_CR52","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1159\/000188383","volume":"69","author":"J Seino","year":"1995","unstructured":"Seino J, Narita M, Noshiro H, Sato K, Sato H, Saito T, Abe K (1995) Alteration of C3 nephritic factor in a patient with membrano-proliferative glomerulonephritis type II. Nephron 69:114\u2013115","journal-title":"Nephron"},{"key":"3989_CR53","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/01.md.0000111061.69212.59","volume":"83","author":"A Misra","year":"2004","unstructured":"Misra A, Peethambaram A, Garg A (2004) Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature. Medicine (Baltimore) 83:18\u201334","journal-title":"Medicine (Baltimore)"},{"key":"3989_CR54","first-page":"609","volume":"87","author":"MJ Walport","year":"1994","unstructured":"Walport MJ, Davies KA, Botto M, Naughton MA, Isenberg DA, Biasi D, Powell RJ, Cheung NT, Struthers GR (1994) C3 nephritic factor and SLE: report of four cases and review of the literature. QJM 87:609\u2013615","journal-title":"QJM"},{"key":"3989_CR55","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/ki.2012.384","volume":"83","author":"S Sethi","year":"2013","unstructured":"Sethi S, Fervenza FC, Zhang Y, Zand L, Meyer NC, Borsa N, Nasr SH, Smith RJ (2013) Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement. Kidney Int 83:293\u2013299","journal-title":"Kidney Int"},{"key":"3989_CR56","first-page":"161","volume":"25","author":"JM Rasmussen","year":"1988","unstructured":"Rasmussen JM, Teisner B, Weihe P, Mathiassen B, Petersen T, Isager H (1988) Screening for complement deficiencies in patients surviving from epidemic meningococcal disease. J Clin Lab Immunol 25:161\u2013165","journal-title":"J Clin Lab Immunol"},{"key":"3989_CR57","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/0090-1229(90)90018-L","volume":"57","author":"RE Spitzer","year":"1990","unstructured":"Spitzer RE, Stitzel AE, Tsokos GC (1990) Production of IgG and IgM autoantibody to the alternative pathway C3 convertase in normal individuals and patients with membranoproliferative glomerulonephritis. Clin Immunol Immunopathol 57:10\u201318","journal-title":"Clin Immunol Immunopathol"},{"key":"3989_CR58","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/0090-1229(89)90141-4","volume":"50","author":"CW Clardy","year":"1989","unstructured":"Clardy CW, Forristal J, Strife CF, West CD (1989) A properdin dependent nephritic factor slowly activating C3, C5, and C9 in membranoproliferative glomerulonephritis, types I and III. Clin Immunol Immunopathol 50:333\u2013347","journal-title":"Clin Immunol Immunopathol"},{"key":"3989_CR59","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/ki.2008.657","volume":"75","author":"S Sethi","year":"2009","unstructured":"Sethi S, Gamez JD, Vrana JA, Theis JD, Bergen HR 3rd, Zipfel PF, Dogan A, Smith RJ (2009) Glomeruli of dense deposit disease contain components of the alternative and terminal complement pathway. Kidney Int 75:952\u2013960","journal-title":"Kidney Int"},{"key":"3989_CR60","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/ki.2012.212","volume":"82","author":"S Sethi","year":"2012","unstructured":"Sethi S, Fervenza FC, Zhang Y, Zand L, Vrana JA, Nasr SH, Theis JD, Dogan A, Smith RJ (2012) C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int 82:465\u2013473","journal-title":"Kidney Int"},{"key":"3989_CR61","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00467-010-1734-4","volume":"26","author":"V Leroy","year":"2011","unstructured":"Leroy V, Fremeaux-Bacchi V, Peuchmaur M, Baudouin V, Deschenes G, Macher MA, Loirat C (2011) Membranoproliferative glomerulonephritis with C3NeF and genetic complement dysregulation. Pediatr Nephrol 26:419\u2013424","journal-title":"Pediatr Nephrol"},{"key":"3989_CR62","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1681\/ASN.2010080795","volume":"22","author":"MA Abrera-Abeleda","year":"2011","unstructured":"Abrera-Abeleda MA, Nishimura C, Frees K, Jones M, Maga T, Katz LM, Zhang Y, Smith RJ (2011) Allelic variants of complement genes associated with dense deposit disease. J Am Soc Nephrol 22:1551\u20131559","journal-title":"J Am Soc Nephrol"},{"key":"3989_CR63","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1172\/JCI109787","volume":"65","author":"L Halbwachs","year":"1980","unstructured":"Halbwachs L, Leveille M, Lesavre P, Wattel S, Leibowitch J (1980) Nephritic factor of the classical pathway of complement: immunoglobulin G autoantibody directed against the classical pathway C3 convetase enzyme. J Clin Invest 65:1249\u20131256","journal-title":"J Clin Invest"},{"key":"3989_CR64","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.4049\/jimmunol.125.5.2051","volume":"125","author":"MR Daha","year":"1980","unstructured":"Daha MR, van Es LA (1980) Relative resistance of the F-42-stabilized classical pathway C3 convertase to inactivation by C4-binding protein. J Immunol 125:2051\u20132054","journal-title":"J Immunol"},{"key":"3989_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1084\/jem.154.1.1","volume":"154","author":"I Gigli","year":"1981","unstructured":"Gigli I, Sorvillo J, Mecarelli-Halbwachs L, Leibowitch J (1981) Mechanism of action of the C4 nephritic factor. Deregulation of the classical pathway of C3 convertase. J Exp Med 154:1\u201312","journal-title":"J Exp Med"},{"key":"3989_CR66","first-page":"82","volume":"76","author":"Y Tanuma","year":"1989","unstructured":"Tanuma Y, Ohi H, Watanabe S, Seki M, Hatano M (1989) C3 nephritic factor and C4 nephritic factor in the serum of two patients with hypocomplementaemic membranoproliferative glomerulonephritis. Clin Exp Immunol 76:82\u201385","journal-title":"Clin Exp Immunol"},{"key":"3989_CR67","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/j.1365-2249.1994.tb06530.x","volume":"95","author":"H Ohi","year":"1994","unstructured":"Ohi H, Yasugi T (1994) Occurrence of C3 nephritic factor and C4 nephritic factor in membranoproliferative glomerulonephritis (MPGN). Clin Exp Immunol 95:316\u2013321","journal-title":"Clin Exp Immunol"},{"key":"3989_CR68","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1681\/ASN.2015040433","volume":"26","author":"HT Cook","year":"2015","unstructured":"Cook HT (2015) C4d staining in the diagnosis of C3 glomerulopathy. J Am Soc Nephrol 26:2609\u20132611","journal-title":"J Am Soc Nephrol"},{"key":"3989_CR69","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00431-013-2245-7","volume":"173","author":"J Prasto","year":"2014","unstructured":"Prasto J, Kaplan BS, Russo P, Chan E, Smith RJ, Meyers KE (2014) Streptococcal infection as possible trigger for dense deposit disease (C3 glomerulopathy). Eur J Pediatr 173:767\u2013772","journal-title":"Eur J Pediatr"},{"key":"3989_CR70","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1053\/j.ajkd.2012.02.329","volume":"60","author":"KA Vernon","year":"2012","unstructured":"Vernon KA, Goicoechea de Jorge E, Hall AE, Fremeaux-Bacchi V, Aitman TJ, Cook HT, Hangartner R, Koziell A, Pickering MC (2012) Acute presentation and persistent glomerulonephritis following streptococcal infection in a patient with heterozygous complement factor H-related protein 5 deficiency. Am J Kidney Dis 60:121\u2013125","journal-title":"Am J Kidney Dis"},{"key":"3989_CR71","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1084\/jem.175.4.939","volume":"175","author":"S Meri","year":"1992","unstructured":"Meri S, Koistinen V, Miettinen A, Tornroth T, Seppala IJ (1992) Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis. J Exp Med 175:939\u2013950","journal-title":"J Exp Med"},{"key":"3989_CR72","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/nri2620","volume":"9","author":"PF Zipfel","year":"2009","unstructured":"Zipfel PF, Skerka C (2009) Complement regulators and inhibitory proteins. Nat Rev Immunol 9:729\u2013740","journal-title":"Nat Rev Immunol"},{"key":"3989_CR73","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.4049\/jimmunol.163.8.4590","volume":"163","author":"TS Jokiranta","year":"1999","unstructured":"Jokiranta TS, Solomon A, Pangburn MK, Zipfel PF, Meri S (1999) Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H. J Immunol 163:4590\u20134596","journal-title":"J Immunol"},{"key":"3989_CR74","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.1093\/ndt\/gfr436","volume":"26","author":"N Lorcy","year":"2011","unstructured":"Lorcy N, Rioux-Leclercq N, Lombard ML, Le Pogamp P, Vigneau C (2011) Three kidneys, two diseases, one antibody? Nephrol Dial Transplant 26:3811\u20133813","journal-title":"Nephrol Dial Transplant"},{"key":"3989_CR75","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.2215\/CJN.06180710","volume":"6","author":"F Bridoux","year":"2011","unstructured":"Bridoux F, Desport E, Fremeaux-Bacchi V, Chong CF, Gombert JM, Lacombe C, Quellard N, Touchard G (2011) Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association? Clin J Am Soc Nephrol 6:2165\u20132174","journal-title":"Clin J Am Soc Nephrol"},{"key":"3989_CR76","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrneph.2016.99","volume":"12","author":"MA Dragon Durey","year":"2016","unstructured":"Dragon Durey MA, Sinha A, Togarsimalemath SK, Bagga A (2016) Anti-complement-factor H-associated glomerulopathies. Nat Rev Nephrol 12:563\u2013578","journal-title":"Nat Rev Nephrol"},{"key":"3989_CR77","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1093\/ckj\/sfs002","volume":"5","author":"P Nozal","year":"2012","unstructured":"Nozal P, Strobel S, Ibernon M, Lopez D, Sanchez-Corral P, Rodriguez de Cordoba S, Jozsi M, Lopez-Trascasa M (2012) Anti-factor H antibody affecting factor H cofactor activity in a patient with dense deposit disease. Clin Kidney J 5:133\u2013136","journal-title":"Clin Kidney J"},{"key":"3989_CR78","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.4049\/jimmunol.1200679","volume":"189","author":"C Blanc","year":"2012","unstructured":"Blanc C, Roumenina LT, Ashraf Y, Hyvarinen S, Sethi SK, Ranchin B, Niaudet P, Loirat C, Gulati A, Bagga A, Fridman WH, Sautes-Fridman C, Jokiranta TS, Fremeaux-Bacchi V, Dragon-Durey MA (2012) Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome. J Immunol 189:3528\u20133537","journal-title":"J Immunol"},{"key":"3989_CR79","doi-asserted-by":"publisher","first-page":"9500","DOI":"10.1074\/jbc.M114.630871","volume":"290","author":"A Bhattacharjee","year":"2015","unstructured":"Bhattacharjee A, Reuter S, Trojnar E, Kolodziejczyk R, Seeberger H, Hyvarinen S, Uzonyi B, Szilagyi A, Prohaszka Z, Goldman A, Jozsi M, Jokiranta TS (2015) The major autoantibody epitope on factor H in atypical hemolytic uremic syndrome is structurally different from its homologous site in factor H-related protein 1, supporting a novel model for induction of autoimmunity in this disease. J Biol Chem 290:9500\u20139510","journal-title":"J Biol Chem"},{"key":"3989_CR80","doi-asserted-by":"publisher","first-page":"770","DOI":"10.2215\/CJN.06760909","volume":"5","author":"S Sethi","year":"2010","unstructured":"Sethi S, Zand L, Leung N, Smith RJ, Jevremonic D, Herrmann SS, Fervenza FC (2010) Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy. Clin J Am Soc Nephrol 5:770\u2013782","journal-title":"Clin J Am Soc Nephrol"},{"key":"3989_CR81","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s00467-013-2711-5","volume":"29","author":"C Rousset-Rouviere","year":"2014","unstructured":"Rousset-Rouviere C, Cailliez M, Garaix F, Bruno D, Laurent D, Tsimaratos M (2014) Rituximab fails where eculizumab restores renal function in C3nef-related DDD. Pediatr Nephrol 29:1107\u20131111","journal-title":"Pediatr Nephrol"},{"key":"3989_CR82","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1056\/NEJMc1112273","volume":"366","author":"E Daina","year":"2012","unstructured":"Daina E, Noris M, Remuzzi G (2012) Eculizumab in a patient with dense-deposit disease. N Engl J Med 366:1161\u20131163","journal-title":"N Engl J Med"},{"key":"3989_CR83","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","volume":"91","author":"TH Goodship","year":"2017","unstructured":"Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Fremeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodriguez de Cordoba S, Roumenina LT, Sethi S, Smith RJ (2017) Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \"Kidney Disease: Improving Global Outcomes\" (KDIGO) Controversies Conference. Kidney Int 91:539\u2013551","journal-title":"Kidney Int"},{"key":"3989_CR84","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/ki.2015.227","volume":"88","author":"C Rabasco","year":"2015","unstructured":"Rabasco C, Cavero T, Roman E, Rojas-Rivera J, Olea T, Espinosa M, Cabello V, Fernandez-Juarez G, Gonzalez F, Avila A, Baltar JM, Diaz M, Alegre R, Elias S, Anton M, Frutos MA, Pobes A, Blasco M, Martin F, Bernis C, Macias M, Barroso S, de Lorenzo A, Ariceta G, Lopez-Mendoza M, Rivas B, Lopez-Revuelta K, Campistol JM, Mendizabal S, de Cordoba SR, Praga M (2015) Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int 88:1153\u20131160","journal-title":"Kidney Int"},{"key":"3989_CR85","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/nrneph.2017.156","volume":"14","author":"D Ricklin","year":"2017","unstructured":"Ricklin D, Mastellos DC, Reis ES, Lambris JD (2017) The renaissance of complement therapeutics. Nat Rev Nephrol 14:26","journal-title":"Nat Rev Nephrol"},{"key":"3989_CR86","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1055\/s-0034-1375299","volume":"40","author":"M Vivarelli","year":"2014","unstructured":"Vivarelli M, Emma F (2014) Treatment of C3 glomerulopathy with complement blockers. Semin Thromb Hemost 40:472\u2013477","journal-title":"Semin Thromb Hemost"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-3989-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-018-3989-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-3989-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T23:18:35Z","timestamp":1693696715000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-018-3989-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,9]]},"references-count":86,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["3989"],"URL":"https:\/\/doi.org\/10.1007\/s00467-018-3989-0","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,9]]},"assertion":[{"value":"8 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Marina Noris has received honoraria from Alexion Pharmaceuticals for giving lectures and participating in advisory boards. None of these activities have had any influence on the results or interpretation in this article. GR has consultancy agreements with AbbVie*, Alexion Pharmaceuticals*, Bayer Healthcare*, Reata Pharmaceuticals*, Novartis Pharma*, AstraZeneca*, Otsuka Pharmaceutical Europe* and Concert Pharmaceuticals*.*No personal remuneration is accepted, and compensations are paid to his institution for research and educational activities. The other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}